A question on the US, basically to understand the concentration risk. Can you share what your top three products would contribute to the US sales?
Some broad numbers like 40% plus or less than 40% somewhere?
Questions across 2 calls
Vishal Manchanda
Systematics
Cipla Limited
In the US, can you update on what's our market share in Luprolide?
So, it starts ramping up as we have seen in case of Lanreotide, right?